The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

• Nikola Geskovski,
• Nadica Matevska-Geshkovska,
• Simona Dimchevska Sazdovska,
• Marija Glavas Dodov,
• Kristina Mladenovska and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31

• chemotherapeutic protocols. Keywords: CD44; EGFR; liquid tumors; molecular tumor targeting; myeloid leukemia; solid tumors; surface-engineered nanoparticles; Introduction The conventional chemotherapy regimens of both liquid (hematological) and solid tumors are challenged by their lack of targeting ability

• therapy. Unlike solid tumors, which necessitate nanoscale drug delivery system (NDDSs) to reach a specific site of action, liquid tumors are mainly spread throughout the blood circulation. In fact, the barriers that apply to the NDDSs for solid tumor targeting usually do not exist in the case of liquid

• conventional treatment protocols due to unfavorable physicochemical and pharmacokinetic properties, nanotechnology offers strategies for targeting a variety of leukemia cell populations. Even though liquid tumors mainly reside in the blood circulation and seem readily available for chemotherapy, the